Novavax, Inc. (Nasdaq: NVAX), an American biotechnology company, announced on Friday that it has received expanded authorisation from Health Canada for its Nuvaxovid (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunisation to prevent COVID-19.

The vaccine will be a homologous booster in adults aged 18 and older.

Nuvaxovid has received expanded authorisation based on data from a phase two trials carried out in South Africa and from the Prevent-19 Phase three trial conducted in the United States and Mexico. Under the trials, a single booster dose of the product was administered to healthy adult participants around 6 to 11 months after their primary series of two doses administered three weeks apart. The third (booster) dose developed increased immune responses to levels comparable to or exceeding those associated with protection against COVID-19 in Phase three clinical trials.